Fulgent Genetics (FLGT) to Release Quarterly Earnings on Friday

Fulgent Genetics (NASDAQ:FLGT) is scheduled to be announcing its earnings results before the market opens on Friday, May 3rd. Analysts expect the company to announce earnings of ($0.33) per share for the quarter. Fulgent Genetics has set its FY24 guidance at -$1.05 EPS and its FY 2024 guidance at -1.050–1.050 EPS.Investors interested in registering for the company’s conference call can do so using this link.

Fulgent Genetics (NASDAQ:FLGT) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.61. The firm had revenue of $70.51 million for the quarter, compared to analysts’ expectations of $67.14 million. Fulgent Genetics had a negative return on equity of 3.04% and a negative net margin of 58.03%. On average, analysts expect Fulgent Genetics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fulgent Genetics Stock Performance

FLGT stock opened at $20.03 on Friday. The stock has a market capitalization of $598.90 million, a price-to-earnings ratio of -3.55 and a beta of 1.43. Fulgent Genetics has a 1 year low of $19.88 and a 1 year high of $44.09. The stock’s fifty day moving average is $22.24 and its two-hundred day moving average is $25.18.

Analyst Ratings Changes

Separately, Piper Sandler cut their target price on Fulgent Genetics from $28.00 to $25.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 6th.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.